TANDEM DIABETES CARE INCTNDMEarnings & Financial Report
Tandem Diabetes Care, Inc. is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.
TNDM Q1 FY2026 Key Financial Metrics
Revenue
$247.2M
Gross Profit
$136.8M
Operating Profit
$93.0M
Net Profit
$-20.4M
Gross Margin
55.3%
Operating Margin
37.6%
Net Margin
-8.2%
YoY Growth
5.5%
EPS
$-0.30
TANDEM DIABETES CARE INC Q1 FY2026 Financial Summary
TANDEM DIABETES CARE INC reported revenue of $247.2M (up 5.5% YoY) for Q1 FY2026, with a net profit of $-20.4M (-8.2% margin). Cost of goods sold was $110.4M, operating expenses totaled $43.8M.
Key Financial Metrics
| Total Revenue | $247.2M |
|---|---|
| Net Profit | $-20.4M |
| Gross Margin | 55.3% |
| Operating Margin | 37.6% |
| Report Period | Q1 FY2026 |
TANDEM DIABETES CARE INC Annual Revenue by Year
TANDEM DIABETES CARE INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.0B).
TANDEM DIABETES CARE INC Quarterly Revenue & Net Profit History
TANDEM DIABETES CARE INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $247.2M | +5.5% | $-20.4M | -8.2% |
| Q4 FY2025 | $290.4M | +2.7% | $-589.0K | -0.2% |
| Q3 FY2025 | $249.3M | +2.2% | $-21.2M | -8.5% |
| Q2 FY2025 | $240.7M | +8.5% | $-52.4M | -21.8% |
| Q1 FY2025 | $234.4M | +22.3% | $-130.6M | -55.7% |
| Q4 FY2024 | $282.6M | +43.6% | $755.0K | 0.3% |
| Q3 FY2024 | $244.0M | +31.4% | $-23.3M | -9.5% |
| Q2 FY2024 | $221.9M | +13.3% | $-30.8M | -13.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $221.9M | $244.0M | $282.6M | $234.4M | $240.7M | $249.3M | $290.4M | $247.2M |
| YoY Growth | 13.3% | 31.4% | 43.6% | 22.3% | 8.5% | 2.2% | 2.7% | 5.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $937.5M | $957.7M | $967.7M | $922.1M | $875.7M | $874.7M | $881.1M | $1.15B |
| Liabilities | $703.6M | $720.0M | $704.6M | $766.9M | $742.5M | $741.7M | $725.9M | $1.02B |
| Equity | $233.9M | $237.7M | $263.1M | $155.3M | $133.3M | $133.0M | $155.2M | $132.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-5.3M | $26.8M | $10.7M | $-18.3M | $-9.5M | $8.3M | $9.8M |